Personal genetics company 23andMe bought a patient social networking site called CureTogether earlier this week, a move that will expand the Silicon Valley-based company’s ability to mine data from its patients for its own research.
CureTogether is an online forum with some 25,000 members who share information about their illness, and personal anecdotes about the effects of treatments and lifestyle choices on their symptoms.
23andMe sells DNA tests directly to consumers who send a spit sample to the company for genomic screening of up to 1 million genetic variants, which are a mix of both recreational (e.g. the genetic basis for tongue rolling) and serious medical traits (e.g. genetic factors associated with Parkinson’s Disease) as well as variants that indicate a customer’s ancestry.
The amount of the purchase was not reported and is 23andMe’s first acquisition, according to the San Francisco Business Times.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
How AI can help us understand how cells work—and help cure diseases
A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.